Browse Articles
Discover research articles across all indexed journals
Site-specific conjugation of PEG12-PSMA ligand to dianthin by click chemistry to kill prostate cancer cells in the presence of the endosomal escape enhancer SO1861.
179 Background: Prostate-specific membrane antigen (PSMA) is overexpressed in many prostate cancer cells and is a promising target for the diagnosis and treatment of prostate cancer. This study aims to develop a novel PSMA-targeted ligand-toxin conjugate that kills prostate cancer cells by ribosomal inactivation, and to evaluate its potency in vitro . Methods: A modified single-cysteine-containing ribosome-inactivating protein (Dianthin-Cys) was recombinantly expressed in NiCo21 cells and purified by Ni-NTA column chromatography followed by cation exchange chromatography. An azido-PSMA ligand was site-specifically coupled to Dianthin-Cys by click chemistry via a maleimide-PEG12-DBCO linker (D-PSMA). Ribosomal N-glycosidase activity of Dianthin-Cys was measured by an adenine-release assay. Cytotoxicity was assessed with or without the endosomal escape enhancer SO1861 to determine IC 50 values in PSMA-positive C4-2 and LNCap cells and in PSMA-negative DU145 and PC-3 cells. Fluorescently labeled D-PSMA was used for confocal microscopy to visualize surface binding and internalization of the conjugates in each cell line. Lysosomal trafficking was assessed with LysoTracker Green DND-26. Results: SDS-PAGE and mass spectrometry indicated high purity of D-PSMA conjugates, with a molecular mass of ~32 kDa. Western blotting confirmed strong PSMA expression in C4-2 and LNCap cells but not in DU145 and PC-3 cells. The adenine release activity of D-PSMA was 71.93 pmol/pmol/h. Cytotoxicity assays showed prominent cell death in the presence of SO1861, with IC 50 values of 0.738 pM and 0.695 pM in C4-2 and LNCap cells, respectively, and 55 pM and 26 pM in DU145 and PC-3 cells, respectively. No cytotoxicity was observed in the absence of SO1861 within the tested concentration range (up to 3.1 nM). Prominent surface binding and internalization of D-PSMA were observed in C4-2 and LNCap cells, whereas DU145 and PC-3 cells showed no visible binding or internalization. Both C4-2 and LNCap cells showed colocalization of D-PSMA with Lysotracker. Conclusions: The findings of this study demonstrate that D-PSMA is a PSMA-specific and effective therapeutic agent when combined with SO1861 for the treatment of prostate cancer.
Origin of Reversible Interlayer-Disorder-Induced Phase Transitions in Layered Sodium Manganese Oxide Cathodes
Machine Learning‐Optimized Single‐Atom Catalysts Enable Microenvironment‐Adaptive Chemodynamic‐Bioorthogonal Cancer Therapy
ABSTRACT Chemodynamic therapy (CDT), which harnesses endogenous chemical energy within the tumor microenvironment (TME), has shown high potential for precise cancer treatment. However, its efficacy is often limited by the mildly acidic and reductive nature of the TME that compromises catalyst stability and activity. Developing catalysts capable of maintaining robust performance under such physiological constraints remains a key challenge. Herein, we report a programmable dual‐catalytic platform that integrates machine learning‐guided design with atomic‐level precision. Through predictive modeling, we establish quantitative structure‐performance relationships that guided the rational synthesis of iron single‐atoms (Fe‐N 5 SAs). The Fe‐N 5 SAs demonstrate exceptional chemodynamic reactivity and environmental stability within the complex TME, efficiently converting endogenous hydrogen peroxide into hydroxyl radicals for precise tumor ablation. Moreover, Fe‐N 5 SAs exhibit potent bioorthogonal catalytic activity, enabling in situ prodrug activation and localized synthesis of doxorubicin under physiological conditions. This synergistic CDT‐bioorthogonal dual‐catalytic mechanism achieves tumor‐selective, stimulus‐free, and combinatorial therapy, markedly enhancing overall antitumor efficacy. This study establishes a machine learning‐guided framework for single‐atom catalyst design and expands the frontiers of metal catalysis in biomedical applications.
Correction: Protein kinase a regulates cyclooxygenase-2 expression through the RNA-binding proteins HuR and TTP
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy
We report correlative circulating tumor DNA (ctDNA) analyses from TRANSFORM (ClinicalTrials.gov identifier: NCT03575351 ) evaluating lisocabtagene maraleucel (liso-cel) versus standard of care (salvage immunochemotherapy, high-dose chemotherapy, autologous stem cell transplantation [ASCT]) in second-line large B-cell lymphoma (LBCL). ctDNA association with efficacy was investigated at predefined time points (random assignment, day 43, day 64, and day 126 [3 months after liso-cel, approximately 2 months after ASCT]) for 136 patients using ultrasensitive PhasED-Seq. ctDNA clearance (measurable residual disease [MRD] neg ) predicted longer event-free survival (EFS) at all time points in both arms, with significantly more liso-cel–treated patients achieving MRD neg . Liso-cel demonstrated superior outcomes versus ASCT, including longer EFS, progression-free survival (PFS), and duration of response among patients in complete response (CR) and MRD neg . ctDNA re-emergence in patients with CR after ASCT confirmed its potential in predicting relapse. MRD neg remained significantly associated with EFS after adjusting for positron emission tomography (PET) response, while interaction testing revealed a significant interaction between PET status and treatment arm for EFS. Liso-cel achieved deeper, more durable molecular clearance by ctDNA, consistent with superior EFS and PFS versus ASCT for second-line LBCL treatment. ctDNA-MRD provided prognostic value beyond PET, supporting its role as a complementary biomarker for treatment response and relapse prediction.
Solvent-Driven Biphasic Architectures in Polymer Gels via Polymerization-Induced Solvent Phase Separation
Microdroplet-Enabled Interfacial Electron Transfer Accelerates Schiff Base Condensation for Ultrafast Covalent Organic Framework Synthesis
Programming Insulator‐to‐Metallic Transport in Insulating Materials via Surface Single‐Atom Engineering
ABSTRACT Reconfigurable electronic states in insulating materials enable metal‐like transport while preserving the intrinsic robustness and functional versatility of insulating hosts, thereby redefining materials beyond the conventional metal–insulator dichotomy. However, obtaining such states remains extremely challenging owing to strong electronic localization inherent in insulating materials. We demonstrate a universal surface single‐atom engineering strategy for linear and deep programming of electronic transport in insulating oxides and nitrides, including SiO 2 , Al 2 O 3 , and BN, by selectively inducing local symmetry breaking, effective bandgap compression, and impurity‐band percolation. Consequently, this strategy continuously narrows the bandgap and ultimately yields metallic transport characteristics with anomalously minimal temperature dependence. Furthermore, we apply single‐atom‐anchored SiO 2 , an intrinsically electromagnetic wave‐transparent material, to shielding with a record‐high effectiveness of 98.6% for an ultrathin 80 µm film that also maintains stable performance over a temperature range of 300–800 K. This counterintuitive performance defies the conventional paradigm, demonstrating that an intrinsically insulating material can achieve electromagnetic shielding comparable to state‐of‐the‐art metals while avoiding the temperature‐induced performance degradation of metallic shielding materials. Overall, we believe that this study establishes single‐atom band engineering as a general strategy for programming electronic transport in insulating materials, with broad implications for advanced electronics and unconventional functionalities.
The N-terminal domain of the endoplasmic reticulum-resident chaperone Grp94 functions in aggregation prevention
Effect of long-limb Roux-en-Y reconstruction on early glycemic control compared with Billroth II after subtotal gastrectomy in patients with type 2 diabetes and gastric cancer: 6-Month interim analysis of the STARDOM trial.
157 Background: Gastrectomy can induce improvement in type 2 diabetes (T2DM), yet the metabolic impact may vary according to reconstruction method. Whether reconstruction strategy influences diabetes outcomes in gastric cancer remains unclear. The STARDOM trial was designed to determine the differential metabolic effects of Billroth II (BII), conventional Roux-en-Y (CRY), and long-limb Roux-en-Y (LRY) reconstruction after subtotal gastrectomy. Methods: STARDOM is a prospective, multicenter, phase III randomized controlled trial enrolling patients with stage I–II distal gastric adenocarcinoma, T2DM, and BMI ≥23 kg/m². Patients were randomized 1:1:1 to BII, CRY, or LRY reconstruction. The primary endpoint is biochemical improvement of diabetes at 12 months, defined as HbA1c <6.5% without antidiabetic medication. We report prespecified 6-month interim outcomes. Results: Sixty patients were randomized (BII n=20, CRY n=19, LRY n=21) with balanced baseline characteristics. At 6 months, HbA1c <6.5% was achieved in 28.6% of BII, 53.8% of CRY, and 70.6% of LRY patients. LRY demonstrated a significantly higher response rate compared with BII (p=0.032), representing more than a twofold increase in diabetes control. Mean HbA1c at 6 months was lowest in LRY (6.17%) compared with CRY (6.55%) and BII (6.50%). Weight loss was comparable across groups, suggesting a weight-independent metabolic effect. Surgical morbidity did not differ significantly. Conclusions: Long-limb Roux-en-Y reconstruction produced superior early glycemic control compared with Billroth II after gastrectomy for gastric cancer, without increased morbidity. These findings support reconstruction-dependent metabolic benefit and may influence surgical strategy in patients with gastric cancer and T2DM. (ClinicalTrial.gov ID: NCT04284943.) Clinical trial information: NCT04284943 . Six-month outcomes from the STARDOM trial. Billroth II (n=14) Conventional RY (n=13) Long-limb RY (n=17) P value CRY vs BII LRY vs BII LRY vs BII Glycated hemoglobin Level, n (%) < 6.5% 4 (28.6%) 7 (53.8%) 12 (70.6%) 0.066 0.252 0.032 < 6.0% 2 (14.3%) 5 (38.5%) 7 (41.2%) 0.231 0.209 0.132 At baseline, %, mean (SD) 8.1 (1.5) 7.7 (0.9) 8.0 (1.6) 0.741 0.382 0.755 At 6 months, %, mean (SD) 6.5 (0.6) 6.6 (0.9) 6.2 (1.0) 0.416 0.856 0.268 Fasting glucose At baseline, mg/dL, mean (SD) 163.9 (107.4) 183.5 (74.0) 156.8 (56.1) 0.660 0.582 0.827 At 6 months, mg/dL, mean (SD) 121.2 (37.8) 129.9 (28.9) 119.1 (18.9) 0.580 0.506 0.852 Change from baseline, mg/dL, mean (SD) -42.6 (113.7) -53.6 (68.9) -37.7 (62.8) 0.874 0.763 0.886 Abbreviations: BII, Billroth II; CRY, conventional Roux-en-Y; LRY, long-limb Roux-en-Y; HbA1c, glycated hemoglobin; SD, standard deviation; BMI, body mass index.
Hydrogen Bonding within Dynamic <sup>19</sup> F-Tagged Oligothiourea Foldamers in Solution and in Membranes
Directional Concerted Proton‐Electron Transfer in COFs for Efficient Photocatalytic H <sub>2</sub> O <sub>2</sub> Production
ABSTRACT Photocatalytic two‐electron oxygen reduction reaction (2e − ORR) offers a sustainable route for green H 2 O 2 synthesis. However, its efficiency is fundamentally constrained by the kinetic mismatch between proton transfer and electron migration across heterogeneous interfaces. Inspired by concerted proton–electron translocation in natural hydrogenases, we report a catechol–triazine donor–acceptor (D–A) covalent organic framework, 2,3‐Dhta‐Tt, for directional concerted proton–electron transfer (DCPET) during photocatalytic H 2 O 2 production. The intrinsic built‐in electric field, combined with a catechol‐derived dynamic proton‐relay network, aligns proton and electron fluxes and establishes a periodic co‐transport channel toward triazine acceptor sites. At the molecular level, the catechol donor units dominate the highest occupied molecular orbital (HOMO), acting simultaneously as photoexcitation centers and initial proton‐release sites, thereby synchronizing proton delivery with electron migration. This vectorial coupling lowers the activation barrier for O─O hydrogenation and promotes highly selective 2e − ORR, affording an H 2 O 2 production rate of 27.22 mmol g −1 h −1 in pure water. The framework also exhibits proton conductivity of 6.09 × 10 −5 S cm −1 and an extended excited‐state lifetime of 94.45 ps. Isotope labeling, operando spectroscopy, and DFT calculations support a proton‐cycling process and directional proton/electron participation. This work advances heterogeneous photocatalyst design beyond conventional PCET cooperativity.
A dual-pathway Wnt-IL-13 fusion protein enhances human intestinal regeneration through tuft cell activation
Analytical cross-sectional study of correlation between plasma D-dimer levels and lymphovascular invasion in operable carcinoma breast.
64 Background: Malignancy is frequently associated with a hypercoagulable state due to tumour-induced activation of coagulation and fibrinolysis. Plasma D-dimer, a fibrin degradation product, has emerged as a potential biomarker of tumour aggressiveness. Lymphovascular invasion (LVI) is a well-established histopathological predictor of metastasis and poor prognosis in breast cancer. This study aimed to evaluate the association between preoperative plasma D-dimer levels and LVI in operable carcinoma breast. Methods: This prospective analytical cross-sectional study was conducted in the Department of Surgical Oncology, Sri Devaraj Urs Medical College, Kolar, between June 2024 and December 2025. Seventy female patients aged ≥18 years with operable carcinoma breast were enrolled. Preoperative plasma D-dimer levels were measured prior to definitive surgery. Patients underwent either breast-conserving surgery or modified radical mastectomy. Histopathological examination assessed LVI status. Statistical analysis evaluated the correlation between D-dimer levels, LVI, tumour stage, and oral contraceptive use. Results: The majority of patients (63.2%) were between 41–60 years. LVI was present in 52.6% of cases. Mean plasma D-dimer levels were significantly higher in patients with LVI compared to those without LVI (825.85 ± 434.77 vs 227.77 ± 152.47; p < 0.001). D-dimer demonstrated excellent diagnostic performance for predicting LVI (sensitivity 98.0%, specificity 97.78%, PPV 98.0%, NPV 97.78%, overall accuracy 97.89%). No significant association was observed between D-dimer levels and oral contraceptive use (p = 0.219). Although LVI prevalence increased with advancing stage, statistical significance was not reached (p = 0.109). Conclusions: Preoperative plasma D-dimer levels show a strong association with lymphovascular invasion in operable breast cancer. D-dimer is a simple, cost-effective, and non-invasive biomarker that may help identify aggressive tumour biology preoperatively. Larger multicentric studies are warranted to validate its role in prognostic stratification and clinical decision-making.
Hierarchical Chiral Self-Assembly of Nanocylinders Composed of Sequence-Defined Mesogenic Dimers
Correction: F2,6BP restores mitochondrial genome integrity in Huntington’s disease
Real-world comparative safety of first-line lorlatinib versus alectinib in metastatic ALK-rearranged non-small cell lung cancer: A propensity score-matched analysis.
283 Background: Lorlatinib and alectinib are both NCCN-preferred first-line therapies for ALK-positive metastatic NSCLC, yet no head-to-head randomized trials exist. Lorlatinib carries a distinct safety profile including hyperlipidemia and CNS effects, while alectinib is associated with hepatotoxicity and GI toxicities. Real-world comparative safety data are needed to inform treatment selection. Methods: We conducted a retrospective propensity score-matched (PSM) cohort study using the TriNetX Global Collaborative Network (171 healthcare organizations). Adults with metastatic NSCLC (ICD-10: C34 + C78/C79) receiving first-line lorlatinib (Cohort A) or alectinib (Cohort B) were identified. PSM was performed on age, sex, race/ethnicity, brain metastases (C79.31), Charlson comorbidity components, and baseline labs (albumin, hemoglobin, creatinine, LDH). Safety outcomes were assessed using risk analysis (odds ratios) and Kaplan-Meier survival analysis (hazard ratios) with outcomes occurring prior to the index event excluded. Results: After PSM, 844 patients were matched per cohort. Median follow-up was 350 days (lorlatinib) vs 697 days (alectinib). Baseline characteristics were well-balanced (all standardized differences < 0.1). Key safety findings are in the Table. Notably, the divergence between risk-based and time-to-event analyses for several outcomes (cognitive disorders, mood disorders, bradycardia) reflects the substantial follow-up imbalance, with alectinib patients having nearly double the observation time. Conclusions: In this large real-world PSM analysis, lorlatinib was associated with significantly higher hypercholesterolemia risk but lower cumulative rates of mood disorders, bradycardia, constipation, and weight gain compared with alectinib. CNS-related effects and time to new intracranial metastases were comparable between the two agents. These findings suggest distinct but manageable safety trade-offs and support individualized first-line ALK-TKI selection. Sensitivity analyses are warranted to account for the observed follow-up asymmetry. Outcome Lorlatinib (%) Alectinib (%) OR (95% CI) HR (95% CI) Hypercholesterolemia 11.1 7.7 1.48 (1.04–2.11)* 2.20 (1.55–3.11)* Cognitive disorders 10.8 14.8 0.70 (0.51–0.94)* 1.06 (0.80–1.42) Mood disorders 5.1 8.7 0.56 (0.37–0.85)* 0.83 (0.55–1.24) Peripheral neuropathy 7.5 8.2 0.91 (0.63–1.32) 1.37 (0.96–1.96) Weight gain 5.6 8.3 0.66 (0.44–0.99)* 1.05 (0.70–1.57) Bradycardia 3.4 6.3 0.53 (0.32–0.85)* 0.76 (0.47–1.23) Intracranial mets 13.5 15.9 0.83 (0.56–1.23) 1.19 (0.83–1.71) Elevated AST/ALT 3.4 5.1 0.65 (0.40–1.07) 0.85 (0.52–1.38) Constipation 13.2 21.1 0.57 (0.43–0.77)* 0.80 (0.61–1.05)
Photoswitchable Radicals as Reporter Spins for Quantum Sensing with Spin Defects in Diamond
Reciprocal compensation of caspase-2 and p53 regulates the DNA damage response in HCT116 colon cancer cells
Circulating tumor cell-based molecular classification to reveal heterogenous subclones in gestational trophoblastic neoplasia.
222 Background: Gestational trophoblastic neoplasia (GTN) is caused by cancerous transformation of placental trophoblastic cells, which can undergo hematogenous spread via circulating tumor cells (CTCs). Due to limited accessibility to tumor tissues, the molecular classification and metastatic evolutionary dynamics of GTN progression remains poorly defined. Methods: We performed molecular subtyping and evolutionary trajectory analysis using single-cell omic profiling of CTCs and patient-matched tumor cells from GTN blood and tissue biopsies respectively. Experimental in vitro and in vivo assays were employed to test the function of disease-driving genes involved in GTN progression. Blood and tissue-based clinical analyses from independent patient samples were carried out to demonstrate the molecular heterogeneity of GTN subclones within individual patients. Results: Three distinct GTN molecular subtypes were identified and validated in clinical samples, including cilia-like subtype marked by FOXJ1 positivity, tuft cell-like subtype driven by POU2F3, and a senescent subset with elevated BHLHE41 expression. Experimental analyses using GTN cell line models confirmed a central role of POU2F3 in driving epithelial–mesenchymal transition (EMT), migration, invasion, and tumorigenesis in vivo . Furthermore, BHLHE41 overexpression is sufficient to drive p53/p21 activation and senescence induction, characterized by β-Galactosidase formation and elevated expression of the senescence-associated secretory phenotype (SASP) signatures. In a prospective cohort of patient blood samples, CTCs overexpressing POU2F3 or BHLHE41 were significantly elevated in the GTN group compared to the benign hydatidiform moles (HM) cases, implicating their translational potential as single-cell liquid biopsy for accurate molecular subtyping and prediction of GTN progression in the absence of tissue biopsies. Conclusions: This study uncovers key molecular subtypes and functional states of GTN using CTC-based single-cell omic analysis, offering a noninvasive approach for disease classification and real-time monitoring in the absence of tumor tissue biopsies.